Underweight ISRG: 20-25% trim on rallies into $400-416, retain 70-80% benchmark weight with covered call overlay, volatility-based stop at $365-375
Underweight ISRG: Three convergent arguments (fundamental quality, structural headwinds, neutral framing) resolve to Underweight with refined execution. Full Sell is wrong—franchise quality and prior ISRG Overweight lesson (+0.9% alpha) justify meaningful exposure at reduced weight. Full Buy is wrong—TTM revenue growth ~10% vs 32x forward P/E with 39% EPS growth consensus creates compression risk; 30Y Treasury at 19-year highs is a structural regime change for long-duration growth multiples. The operative synthesis: trim 20-25% on rallies into $400-416, retain 70-80% benchmark weight, execute covered call overlay now per LIN collar lesson, use volatility-based tactical stop ($365-375, NOT the trader's $475), and pre-commit mandatory Q3 re-evaluation with default trim trigger if procedure growth and gross margin conditions aren't met.
| Position | Action |
|---|---|
| Rallies into $400-416 | Trim 20-25% of current ISRG exposure |
| Q3 earnings (~6-8 weeks) with no reacceleration in US procedure growth AND gross margin below 66% | Trim another 10-15% (default action) |
| $365 support breaks on weekly close | Downgrade to Sell with target $320-340 |
| Insider Form 4 filings show clustered buying (>$1M) before Q3 | Consider upgrade |
| No new longs here; wait for either confirmed daily close above $475 200 SMA with positive MACD divergence OR retest and hold of $332 with bullish momentum | No initiation of new long positions |
ISRG's 33% drawdown represents a multiple compression, not a fundamental deterioration—the company is delivering record operational performance (20%+ revenue growth, 400 bps margin expansion, $2.49B FCF) while competitors face structural barriers, creating a generational entry point at historically cheap valuations with a $500 price target.
| Indicator | Value | Signal |
|---|---|---|
| close_price | 391.18 | neutral |
| 200_sma | 475.43 | bearish |
| 50_sma | 390.42 | neutral |
| 10_ema | 388.43 | bullish |
| rsi_14 | 54.03 | neutral |
| macd | 3.03 | bullish |
| macd_signal | -1.26 | bullish |
| macd_histogram | 4.29 | neutral |
| bollinger_upper | 416.34 | neutral |
| atr_14 | 11.76 | neutral |
| drawdown_peak_to_trough | ~44% | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Competitors are being structurally crowded out by workflow integration barriers, not gaining on ISRG
↩ rebuts: “Bear claim that competition will crush ISRG”
EV: +25% to $500 (Oppenheimer target); +6.4% to $416 (Bollinger UB); +21.5% to $475 (200 SMA reclaim) · concedes: ACA-driven US procedure softness is real but transient; Inventory more than doubled in 3 years ($893M to $1.84B) is a watch item; Bear's near-term concerns are already priced in at $391
ISRG faces a dangerous combination of decelerating fundamentals (10% TTM revenue growth), stretched valuation (45x P/E for decelerating growth), inventory build risk ($1.84B, up 106% in 3 years), real competitive threats from J&J ($400B+ cap, $30B+ R&D), Medtronic Hugo, and Chinese players, and a hostile macro regime with 30Y Treasury at 19-year highs and 85% probability of no Fed cuts through 2026. Technicals confirm a bear-market rally losing steam at the 50 SMA, with the next leg likely targeting $332-$353 versus current $391.
EV: -$15% from $391 to $320-340 target range over 6 months (retest of $332 July low) · concedes: Balance sheet strength ($3.4B+ cash position) is real and provides long-term option value; 45x trailing P/E will compress even if fundamentals stabilize due to rate environment — valuation floor may take time to establish; The technical oversold bounce was expected; the question is whether it's a bottom or dead-cat bounce — evidence suggests the latter
→ vs conservative: Revenue deceleration thesis misreads a hyper-growth compounder normalizing after platform inflection versus actual business deterioration
→ vs conservative: Inventory build interpretation ignores 4.96x current ratio and $9 billion in liquid assets — this is capacity front-loading, not channel stuffing
→ vs conservative: Macro bear case already priced in at 44% drawdown — rate shock and multiple compression have already occurred
→ vs conservative: Sell call at $410 with $475 stop is selling at fresh major-broker upgrade price, guaranteeing underperformance
→ vs conservative: Insider selling is tax planning and 10b5-1 plan activity, not fundamental deterioration signal
→ vs neutral: Wait-and-see stance ignores opportunity cost when Oppenheimer just put out fresh $500 target with 25% implied upside
→ vs neutral: Quiet institutional bid exists with no retail crowding — waiting means missing the easy move
| recovery_from_low | +17.8% | bullish |
| price_vs_200sma_discount | 17.7% | bearish |
Support: 332 · 353 · 379 · 390 | Resistance: 400 · 416 · 475
ISRG is in a short-term recovery within a long-term downtrend, having bounced 17.8% from the July 23 low of $332.02 to the current $391.18, but still trading 17.7% below the 200 SMA ($475.43). Short-term momentum is constructive with MACD above zero and a bullish crossover intact since Aug 7-10, RSI in neutral territory at 54.03 (not overbought), and price above the 10 EMA at $388.43. However, the 50 SMA at $390.42 is still rolling over, the MACD histogram spread is compressing (+4.29 from peak +6.79), and price has pulled back from $401 to $391 since Aug 14. Key resistance is at $416 (Bollinger upper band) and $475 (200 SMA), with support at $390 (50 SMA), $379, $353, and the July crash low of $332. Risk rating is MEDIUM-HIGH; tactical traders should look for buy-on-dips to $379-$385 with ATR-based stops, avoiding aggressive longs above $400 until the 50 SMA slope turns up and price closes above the Bollinger upper band. The $475 zone is a likely distribution point if reached.
Market Cap
$140.15B
Beta
1.46
52-Week High
$603.88
52-Week Low
$328.57
50-Day MA
$391.04
200-Day MA
$476.17
Trailing P/E
44.96x
Forward P/E
32.41x
PEG Ratio
1.93
Price / Book
7.62x
EV / TTM Revenue
~12.3x
FCF Yield (TTM)
~1.87%
Revenue (2022)
$6.22B
Revenue (2023)
$7.12B
Revenue (2024)
$8.35B
Revenue (2025)
$10.06B
TTM Revenue
$11.03B
YoY Revenue Growth (2023)
+14.5%
YoY Revenue Growth (2024)
+17.2%
YoY Revenue Growth (2025)
+20.5%
TTM Gross Profit
$7.36B
TTM EBITDA
$4.18B
TTM Net Income
$3.14B
TTM Operating Margin
33.6%
TTM Net Margin
28.4%
Gross Margin (2022)
67.4%
Gross Margin (2023)
66.4%
Gross Margin (2024)
67.5%
Gross Margin (2025)
66.0%
Operating Margin (2022)
25.3%
Operating Margin (2023)
24.8%
Operating Margin (2024)
28.1%
Operating Margin (2025)
29.3%
Net Margin (2022)
21.3%
Net Margin (2023)
25.2%
Net Margin (2024)
27.8%
Net Margin (2025)
28.4%
Diluted EPS (2022)
$3.65
Diluted EPS (2023)
$5.03
Diluted EPS (2024)
$6.42
Diluted EPS (2025)
$7.87
TTM EPS
$8.70
Forward EPS
$12.07
Book Value / Share
$51.34
ROE
17.4%
ROA
10.5%
Tax Rate (2025)
~13.1%
Revenue CAGR (4Y)
~17%
Net Income CAGR (4Y)
~29%
EPS CAGR (4Y)
~29%
FCF CAGR (4Y)
~37%
R&D (2022)
$879M
R&D (2023)
$999M
R&D (2024)
$1.15B
R&D (2025)
$1.31B
R&D CAGR
~14%
R&D as % of Revenue
~13%
SG&A (2022)
$1.74B
SG&A (2023)
$1.96B
SG&A (2024)
$2.14B
SG&A (2025)
$2.39B
SG&A CAGR
~11%
Cost of Revenue (2022)
$2.03B
Cost of Revenue (2023)
$2.39B
Cost of Revenue (2024)
$2.72B
Cost of Revenue (2025)
$3.42B
Cost of Revenue CAGR
~19%
Cash & Equivalents (2022)
$1.58B
Cash & Equivalents (2023)
$2.75B
Cash & Equivalents (2024)
$2.03B
Cash & Equivalents (2025)
$3.37B
Short-Term Investments (2022)
$2.54B
Short-Term Investments (2023)
$2.47B
Short-Term Investments (2024)
$1.99B
Short-Term Investments (2025)
$2.57B
Long-Term Investments (2022)
$2.62B
Long-Term Investments (2023)
$2.12B
Long-Term Investments (2024)
$4.82B
Long-Term Investments (2025)
$3.10B
Total Liquid Assets (2022)
~$6.74B
Total Liquid Assets (2023)
~$7.34B
Total Liquid Assets (2024)
~$8.83B
Total Liquid Assets (2025)
~$9.03B
Cash + ST Investments (2025)
$5.93B
Long-Term Debt
$0
Total Equity (2022)
$11.04B
Total Equity (2023)
$13.31B
Total Equity (2024)
$16.43B
Total Equity (2025)
$17.82B
Inventory (2022)
$893M
Inventory (2023)
$1.22B
Inventory (2024)
$1.49B
Inventory (2025)
$1.84B
Net PPE (2022)
$2.37B
Net PPE (2023)
$3.54B
Net PPE (2024)
$4.65B
Net PPE (2025)
$5.34B
Current Ratio (2022)
4.4x
Current Ratio (2023)
4.8x
Current Ratio (2024)
4.1x
Current Ratio (2025)
4.96x
Goodwill
$370M
Operating Cash Flow (2022)
$1.49B
Operating Cash Flow (2023)
$1.81B
Operating Cash Flow (2024)
$2.42B
Operating Cash Flow (2025)
$3.03B
Capital Expenditure (2022)
-$532M
Capital Expenditure (2023)
-$1.06B
Capital Expenditure (2024)
-$1.11B
Capital Expenditure (2025)
-$540M
Free Cash Flow (2022)
$958M
Free Cash Flow (2023)
$750M
Free Cash Flow (2024)
$1.30B
Free Cash Flow (2025)
$2.49B
TTM Free Cash Flow
$2.62B
FCF / Net Income Conversion (2025)
~83%
Stock Buybacks (2022)
-$2.61B
Stock Buybacks (2023)
-$416M
Stock Buybacks (2024)
$0
Stock Buybacks (2025)
-$2.30B
Total Buybacks (2022-2025)
~$2.9B
Stock-Based Compensation (2022)
$513M
Stock-Based Compensation (2023)
$593M
Stock-Based Compensation (2024)
$677M
Stock-Based Compensation (2025)
$788M
SBC as % of Revenue
~7%
Da Vinci Installed Base
>9,000 systems
Strengths
Concerns
Intuitive Surgical operates as the dominant player in robotic-assisted surgical systems with the da Vinci platform and a recurring revenue model anchored by instruments, accessories, and services. The company demonstrated accelerating top-line growth (20.5% in 2025 to $10.06B), operating margin expansion to 29.3%, and FCF generation of $2.62B on a fortress balance sheet with ~$9B in liquid assets and zero debt. Valuation at 44.96x trailing P/E and 32.41x forward P/E reflects a premium for quality and growth, with the forward P/E implying ~39% EPS growth expected from the da Vinci 5 platform cycle and Ion adoption. The principal risks are the elevated valuation, recent technical weakness below the 200-day moving average, and inventory buildup that requires continued revenue acceleration to validate.
Macro: Rates and yields are the dominant headwind with 30-year Treasury at 19-year highs; \"Bonds slam stocks\" and tech selloff weighing on Wall Street per Reuters. Middle East geopolitical tensions pushing Strait of Hormuz concerns and crude oil gains, driving traders to energy rotation. Wednesday CPI print (Aug 12) was not dovish enough to catalyze a relief rally for growth. US recession odds at 8% by end-2026 (-1.0pp week) support soft-landing base case. Fed on hold with 85% no-cut probability removes multiple-expansion tailwind. Nasdaq slide driven by chip names (Sandisk, Micron, Credo) under AI pressure.